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Introduction: Although pharmaceutical companies, regulatory authorities, and health
technology assessment (HTA) agencies have been increasingly using decision-making
frameworks, it is not certain whether these enable better quality decision making.
This could be addressed by formally evaluating the quality of decision-making process
within those organizations. The aim of this literature review was to identify current
techniques (tools, questionnaires, surveys, and studies) for measuring the quality of the
decision-making process across the three stakeholders.
Methods: Using MEDLINE, Web of Knowledge, and other Internet-based search
engines, a literature review was performed to systematically identify techniques for
assessing quality of decision making in medicines development, regulatory review, and
HTA. A structured search was applied using key words and a secondary review was
carried out. In addition, the measurement properties of each technique were assessed
and compared. Ten Quality Decision-Making Practices (QDMPs) developed previously
were then used as a framework for the evaluation of techniques identified in the review.
Due to the variation in studies identified, meta-analysis was inappropriate.
Results: This review identified 13 techniques, where 7 were developed specifically
to assess decision making in medicines’ development, regulatory review, or HTA; 2
examined corporate decision making, and 4 general decision making. Regarding how
closely each technique conformed to the 10 QDMPs, the 13 techniques assessed
a median of 6 QDMPs, with a mode of 3 QDMPs. Only 2 techniques evaluated
all 10 QDMPs, namely the Organizational IQ and the Quality of Decision Making
Orientation Scheme (QoDoS), of which only one technique, QoDoS could be applied
to assess decision making of both individuals and organizations, and it possessed
generalizability to capture issues relevant to companies as well as regulatory authorities.
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Conclusion: This review confirmed a general paucity of research in this area, particularly
regarding the development and systematic application of techniques for evaluating
quality decision making, with no consensus around a gold standard. This review has
identified QoDoS as the most promising available technique for assessing decision
making in the lifecycle of medicines and the next steps would be to further test its validity,
sensitivity, and reliability.
Keywords: measurement instrument, quality decision making, QDMPs, R&D, pharmaceutical, regulatory, health
technology assessment
INTRODUCTION
The literature on decision making stretches back over several
centuries and encompasses a wide range of academic
disciplines—from philosophy and history to mathematics
(Buchanan and O’Connell, 2006). More recently, the science
and art of decision making have been established regarding
the psychology of judgment, decision-making styles, as well
as behavioral economics to enable quality decision making
(Thaler and Sustein, 2009; Lovallo and Sibony, 2010; Kahneman,
2011). According to this research, one of the most fundamental
distinctions in decision making is between the quality of the
process and the quality of the outcome, as good decisions
can be made but may lead to an unfavorable outcome due
to uncertainty. Consequently, the two should be evaluated
separately and the quality of the decision-making process will be
the focus of this review.
Although quality is difficult to define due to its subjective
nature, it is nevertheless possible to identify the elements of a
quality decision-making process. Indeed, the general principles
and steps for making a quality decision have been characterized
by a number of academic and consultancy groups (Matheson
and Matheson, 1998; Hammond et al., 1999; Blenko et al., 2010;
SDG, 2011) and include identifying the problem and objectives;
having creative implementable options; obtaining meaningful,
reliable information upon which to base a decision; identifying
clear consequences and trade-offs for each supportive element;
considering uncertainty and eliminating biases; using logically
correct reasoning; and making a commitment to action. More
recently, these principles have been applied across a number of
disciplines such as economics, environmental protection, clinical
practice, nuclear safety, and government affairs, to facilitate
quality decision making (Ratliff et al., 1999; Dowding and
Thompson, 2003; Morton et al., 2009; Thaler and Sustein, 2009;
Wagner, 2013).
However, research on decision making to enable a quality
process during medicines’ development, regulatory review, and
health technology assessment (HTA) is less well-articulated and
it is not certain how it is being applied by organizations and
individuals in companies and agencies. Thismay be because there
is limited awareness regarding the science of decision making in
Abbreviations: EMA, European Medicines Association; FDA, Food and Drug
Administration; HTA, health technology assessment; QDMP, Quality Decision-
Making Practices; QoDoS, Quality of Decision-Making Orientation Scheme; R&D,
research and development.
this area, as well as limited training and education (Bujar et al.,
2016a).
Nevertheless, regulatory authorities, HTA agencies, and
pharmaceutical companies have been using a number of
frameworks for specific decision-making processes in addition
to legislative frameworks that govern organizations. In
particular, the area of benefit-risk assessment has brought
certain concepts in decision making to the forefront
through the usage of qualitative and quantitative tools by
pharmaceutical companies and regulatory authorities (Guo
et al., 2010; EMA, 2011; FDA, 2013; Tafuri, 2013; Leong
et al., 2015; Pignatti et al., 2015), as well as in the area of
HTA regarding inclusion of multiple decision criteria (Cole
et al., 2016) and a structured assessment of comparative
added benefit of a technology against the cost of treatment
(Cherny et al., 2015; Schnipper et al., 2015). The second
key area that has benefitted from more structured decision
making is portfolio management, where companies have
been using frameworks (Sharpe and Keelin, 1998; Cook
et al., 2014) as well as quantitative methods and algorithms
(Hassanzadeh et al., 2011; Jekunen, 2014) in order to analyze
and optimize the portfolio of medicines and ultimately avoid
late terminations in phase III development. The third area has
been around the use of good submission and review practices
by pharmaceutical companies and regulatory authorities,
respectively (WHO, 2015), as well as in HTA agencies to
standardize evidence generation (EUnetHTA, 2016) and
to analyze the various decision-making systems for the
assessment of health technologies (Rogowski et al., 2008).
Finally, pharmaceutical companies, regulatory authorities,
and HTA agencies have developed specific frameworks and
guidelines to formalize the decision-making process of various
committees (EMA, 2007; FDA, 2008; Hassanzadeh et al., 2011;
CADTH, 2012).
Although these frameworks serve their purpose and describe
the specific process steps and principles regarding decision
making during development, review and HTA assessment of
medicines, they do not often account for the subjective elements,
such as behaviors and influences that affect the process with
which individuals and organizations arrive at the final decision.
In order to address this gap, a previous review of recent research
on decision making has resulted in the development of 10
Quality Decision-Making Practices (QDMPs) to enable quality
decision making. These were developed based on outcomes
of semi-structured interviews with 29 key opinion leaders
from regulatory authorities and pharmaceutical companies to
Frontiers in Pharmacology | www.frontiersin.org 2 April 2017 | Volume 8 | Article 189
Bujar et al. Systematic Review: Medicines’ Decision-Making Processes
investigate and identify the important issues that influence
quality decision making (Donelan et al., 2015) and were
considered as relevant to those two stakeholders (Bujar et al.,
2016a). Moreover, the key frameworks used during medicines
development, particularly in the area of benefit-risk assessment
(Leong et al., 2015), as well as the science of decision making
(Matheson and Matheson, 1998; Hammond et al., 1999; Blenko
et al., 2010; SDG, 2011) are underpinned by this set of
holistic practices. The 10 QDMPs are organized into four
areas: “Structure and Approach,” “Evaluation,” “Impact,” and
“Transparency and Communication” (Figure 1; Bujar et al.,
2016b).
As the use of frameworks by regulatory authorities, HTA
agencies and companies increases, questions remain about
whether these frameworks enable better quality decision making.
This could be addressed by formally evaluating the decision-
making process as well as the internal and external challenges
within organizations and across individuals. In the absence of
other validated criteria for evaluating quality decision making
in medicines development, review and HTA, the 10 QDMPs
were then used as a framework for the evaluation of the
quality and generalizability of techniques identified in the
review. As a result, this literature review aimed to identify
current techniques, including tools, questionnaires, surveys
as well as studies that measure the quality of the decision-
making process within regulatory authorities, HTA agencies and
pharmaceutical companies. The objectives were to compare the
existing techniques, assess their measurement properties, identify
research gaps and recommend the way forward. Of interest would
be to find a technique that is applicable to all three stakeholders
in order to have a common platform for discussing, sharing
and comparing issues in quality decision making throughout the
lifecycle of medicines.
METHODS
A systematic review of the literature was undertaken to identify
current approaches for assessing quality decision making in
medicines development, regulatory review, and HTA.
Data Sources
The following databases were searched: MEDLINE (using
PubMed), Web of Knowledge, Google Scholar, and Open Access
theses and dissertations. Gray literature was also searched using
Google. This review was limited to English-language articles and
covered the 20-year period from 1996 to March 2016, which
reflects the proliferation of publications in this area.
Search Terms
Initially, an exploratory search was undertaken using basic terms
as key words including quality, decision making, techniques,
instruments, tools, measurement, regulatory review, medicines
development, and HTA. These were also used to search
gray literature. The following structured search terms were
constructed using PubMed guidelines and MESH terms and
these were used in database searches (Decision∗ OR “decision
mak∗” OR preference∗) AND (“health technology” OR HTA OR
reimbursement OR coverage OR regulat∗ OR R&D OR “research
and development” OR development OR medicine∗) AND (agency
OR committee OR assessor∗ OR reviewer∗ “pharmaceutical
FIGURE 1 | The 10 Quality Decision-Making Practices (QDMPs).
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compan∗” OR industry) AND (measur∗ or metric∗ OR evaluat∗
OR assess∗ OR apprais∗ OR analys∗) AND (technique OR checklist
OR tool OR scale OR feedback OR survey OR questionnaire OR
instrument).
Selection Procedure
The titles and abstracts resulting from this search were
screened for relevance and duplication. The full text studies
were obtained for all titles/abstracts that appeared to meet
the inclusion/exclusion criteria or where there was any
uncertainty. The full text articles were then screened and
literature was also obtained by checking the references of
the included articles as well as by searching the gray
literature.
Selection Criteria
Included were: (1) All articles which identified a technique
(tool, instrument, or questionnaire) for evaluating quality of
decision making; (2) Techniques applicable to the area of
medicines’ development, regulatory, or HTA; (3) Techniques
evaluating the decision, the decision-making process or key
aspect(s) of the process and associated preferences, influences,
and behaviors; (4) Studies that assess the performance of
the technique by evaluating hypothetical or real (historical)
decisions, vignettes, or a reflection of individual style or
approach.
Excluded were (1) General discussions on decision making
and quality within the area of medicines’ development,
review, and HTA; (2) techniques for measuring quality of
decision making used specifically in disciplines other than
medicines’ development, regulatory review, and HTA; (3)
Frameworks for structuring and documenting decision-making
processes and for enabling quality to be built into decision
making.
Data Extraction and Synthesis
The following extracted information were recorded: title of the
technique, decision area (e.g., regulatory advisory committee or
medicines R&D), study subject (e.g., regulatory authority, HTA
agency or industry), subject type (organizations or individuals)
and method.
Assessment of the Techniques
In the absence of an alternative evaluation criteria system that
captures issues relevant to the areas of medicines’ development,
review, and HTA assessment, the 10 QDMPs (Table 1) were
used to evaluate the techniques identified in this review to
ensure that each technique is evaluating all key aspects of quality
decisionmaking. The 10QDMPswere developed based on results
from semi-structured interview with 29 key opinion leaders
from regulatory authorities and pharmaceutical companies to
investigate and identify the important issues that influence
decision making (Donelan et al., 2015). In addition, the key
decision-making frameworks (Hammond et al., 1999; Blenko
et al., 2010; SDG, 2011) as well as benefit-risk assessment
methodologies (Leong et al., 2015; Pignatti et al., 2015) are also
underpinned by these practices. In a subsequent review, these
QDMPs were presented to major pharmaceutical companies and
regulatory authorities, and were considered as appropriate and
relevant (Bujar et al., 2016a).
In addition, the measurement properties of each technique
were assessed in terms of
• Theoretical underpinning (development technique was based
on a well-described methodological framework);
• Psychometric properties (development of technique involved
psychometric tests; content validity, and internal consistency);
• Psychometric evaluations (the validity, reliability, and
sensitivity of the tool was demonstrated);
• Demonstrated practicality (the technique was applied to target
population through pilot studies);
• Generalizability (the technique can be used across industry,
regulatory and HTA); and
• Applicability (the technique is applicable to evaluating
individuals and organizations), which were considered as the
key properties that need to be considered when evaluating
such instruments (McDowell, 2006; Streiner et al., 2015).
Secondary Review
An independent secondary reviewer (JW, see Acknowledgments)
was involved in the development of the search strategy and
selection criteria, as well as article selection and data extraction.
Secondary screening was carried out as follows: MB selected at
random 25% of the full text papers (10 out of 38), which were
re-assessed for inclusion/exclusion by the secondary reviewer
against the criteria. Disagreements were resolved through
discussion, and MB and JW disagreed regarding the inclusion
of one paper. This was resolved by refining the inclusion criteria
to make them more specific. Following this modification, 100%
concordance was reached regarding the included papers. JW also
independently carried out data extraction and a small number
of disagreements were resolved through discussions until full
agreement was reached.
RESULTS
For the purpose of clarity, the key results are presented in three
parts:
• Part 1: Selected articles for review
• Part 2: Identified techniques for evaluating quality of decision
making
• Part 3: Measurement properties of the techniques.
Part 1: Selected Articles for Review
Of 4,782 records, 785 were removed as duplicates and 3,959
were excluded following screening of titles and abstracts.
Out of the 38 full text articles identified, 29 articles were
excluded, and an additional four articles were identified from
references or gray literature (Figure 2). A total of 13 articles
met the inclusion/exclusion criteria, each describing a technique
for evaluating quality of decision making and assessing a
total sample of 2,400 subjects (individuals, organizations, or
medicines).
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TABLE 1 | Description of the 10 QDMPs.
QDMP Description
1. Have a systematic, structured approach to aid
decision making (consistent, predictable, and timely)
• Establish the decision context, objectives and assumptions made.
• Employ frameworks, guidelines and tools for structuring the decision-making process.
• Such an approach should ensure that the process is systematic, which in turn would enable better
consistency compared with similar past decisions, as well as predictability and timeliness.
2. Assign clear roles and responsibilities (decision
makers, advisors, information providers)
• The roles and responsibilities should be clearly defined in terms of individuals who provide information
(including external input), compared with those who advise on the decision or make the final decision.
• The roles and responsibilities of each stakeholder (regulatory authorities, HTA agencies and companies)
should be transparent and well communicated, which should help manage expectations.
3. Assign values and relative importance to decision
criteria
• The relevant criteria for the decision must be determined to ensure that these are in line with the decision
context and overall objective. The criteria should be weighted, for example, by ranking or rating their
relative importance.
4. Evaluate both internal and external influences/biases • Stakeholders need to be aware of personal considerations, subjective influences and biases, acknowledge
them andminimize where possible. Potential biases that need to be considered (Lovallo and Sibony, 2010):
◦ Action-oriented bias: excessive optimism, overconfidence in own judgment and gut-feeling
◦ Interest-oriented bias: inappropriate attachments and misaligned incentives.
◦ Pattern recognition: generalizing based on recent events and seeking out information that supports a
favored decision, which could lead to perpetuating previous mistakes.
◦ Stability bias: preference for status quo and tendency for inertia in the presence of uncertainty.
5. Examine alternative solutions • Decision makers should actively explore possible options during the decision-making process.
• The alternatives need to be assessed, for example using a SWOT analysis, against the relevant decision
criteria in order to determine the best outcome.
6. Consider uncertainty • The extent and limitations of available information need to be judged for each decision criterion in relation
to the alternative options.
• Stakeholders must be explicit regarding acceptability of benefits and harms and how this affects their
approach.
7. Re-evaluate as new information becomes available • This should be actively carried out at all stages during the lifecycle of medicines’ development.
• This may be a safeguard against plunging in or procrastination and/or perpetuating previous mistakes as
well as identifying cultural/organizational/hierarchical influences (e.g., individual vs. organizational, group
successes and group failures).
8. Perform impact analysis of the decision • The impact of the decision needs to be considered on both internal and external stakeholders.
• The analysis must relate to present situation, but also to the future and should take into account elements
of quality/validity of data, political/financial/competitor influences and procedures for similar decisions.
9. Ensure transparency and provide a record trail • It must be clear how the decision was made and details must be consistently documented in a manner
that can be easily followed or audited by appropriate stakeholders.
10. Effectively communicate the basis of the decision • The basis of the decision needs to be appropriately communicated to the relevant stakeholders, both
internally and externally.
Part 2: Identified Techniques for Evaluating
Quality of Decision Making
Out of the 13 techniques identified in this review, seven were
developed specifically to assess decision making in the area
of medicines’ development, regulatory review, or HTA; two
examined corporate decision making, and four were regarding
general decision making. An examination of subject type
demonstrated that the largest proportion of the techniques (6,
46%) assessed decision making of individuals, followed by the
perception of individuals regarding the decision making of the
organization (3, 23%) and then the decision making regarding
themedicine itself (2, 15%). Only two techniques (15%) evaluated
both the decision making of individuals and organizations.
Regarding the ability for each technique to evaluate the
10 QDMPs, the 13 techniques assessed a median of six
QDMPs, with a mode of three QDMPs and only two
techniques accounted for all 10 QDMPs. An examination
of the two most commonly assessed practices indicated
that 10 approaches assessed QDMP four (Evaluate both
internal and external influences/biases), whereas nine approaches
evaluated QDMP 1 (Have a systematic, structured approach
to aid decision making). The two practices that were least
evaluated were QDMP 9 (Ensure transparency and provide
a record trail) and QDMP 10 (Effectively communicate
the basis of the decision), with four and five approaches,
respectively.
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FIGURE 2 | Flow diagram of article selection.
The 13 techniques are listed in Table 2 in descending order of
total number of QDMPs evaluated by the technique, followed by
the year of publication. They are then described in more detail
based on published information.
Organizational IQ Test (Matheson and Matheson,
1998)
This test measures an R&D organization’s adherence to the nine
principles of a smart organization: value creation culture, creative
alternatives, continual learning, embracing uncertainty, outside-
in strategic perspective, systems thinking, open information flow,
alignment and empowerment, and disciplined decision making.
The aim of this test is to benchmark “organizational intelligence”
(i.e., the strategic decision-making abilities of an organization),
identify barriers to decision quality, and prioritize the principles
an organization must focus on to increase its performance
(Matheson and Matheson, 1998).
The nine principles were developed based on previous studies
of decision quality and best practices, which were conducted
in five well-described phases, namely: brief survey to identify
organizations that exemplified high quality R&D decision
making; in depth interviews with 22 companies to identify 45
best practices; questionnaire to create statistical benchmarks for
practices; validation through conformational studies with other
companies; and extension of results to develop the principles.
Subsequently, the test was developed and it consists of 45
questions, with five questions on each of the nine principles
(Matheson and Matheson, 1998) These 45 questions can be
used to evaluate all 10 QDMPs from the point of view of an
organization.
The tool has now been used to assess hundreds of corporations
from the point of view of thousands of individuals regarding
their organization’s decision making, and the results show that a
strong IQ profile correlates positively with financial performance
of organizations, thereby demonstrating the applicability of
the tool (Matheson and Matheson, 2011). The sensitivity or
reproducibility of the tool has not been described. Although the
tool evaluates the full spectrum of organizational-level QDMPs,
the practices of an individual are not evaluated. Furthermore,
the test is specific to R&D organizations and possesses
generalizability to be applied within different departments in
companies including the pharmaceutical industry, but its design
Frontiers in Pharmacology | www.frontiersin.org 6 April 2017 | Volume 8 | Article 189
Bujar et al. Systematic Review: Medicines’ Decision-Making Processes
T
A
B
L
E
2
|
S
u
m
m
a
ry
c
h
a
ra
c
te
ri
s
ti
c
s
o
f
th
e
1
3
te
c
h
n
iq
u
e
s
fo
r
a
s
s
e
s
s
in
g
q
u
a
li
ty
d
e
c
is
io
n
m
a
k
in
g
li
s
te
d
in
d
e
s
c
e
n
d
in
g
o
rd
e
r
o
f
to
ta
l
Q
D
M
P
s
e
v
a
lu
a
te
d
b
y
th
e
te
c
h
n
iq
u
e
.
N
o
.
R
e
fe
rn
c
e
s
T
it
le
D
e
c
is
io
n
a
re
a
S
tu
d
y
s
u
b
je
c
t
S
u
b
je
c
t
ty
p
e
M
e
th
o
d
Q
D
M
P
s
e
v
a
lu
a
te
d
1
2
3
4
5
6
7
8
9
1
0
1
M
a
th
e
so
n
a
n
d
M
a
th
e
so
n
,
1
9
9
8
O
rg
a
n
iz
a
tio
n
a
lI
Q
te
st
C
o
rp
o
ra
te
In
d
u
st
ry
(in
c
lu
d
in
g
p
h
a
rm
.)
O
rg
.
4
5
-i
te
m
q
u
e
st
io
n
n
a
ire
a
ss
e
ss
in
g
n
in
e
p
rin
c
ip
le
s
fo
r
st
ra
te
g
ic
d
e
c
is
io
n
m
a
ki
n
g
in
a
n
o
rg
a
n
iz
a
tio
n
(N
=
1
0
0
s)
X
X
X
X
X
X
X
X
X
X
2
D
o
n
e
la
n
e
t
a
l.,
2
0
1
6
Q
u
a
lit
y
o
f
D
e
c
is
io
n
M
a
ki
n
g
O
rie
n
ta
tio
n
S
c
h
e
m
e
(Q
o
D
o
S
)
in
st
ru
m
e
n
t
M
e
d
ic
in
e
s
R
&
D
/R
e
g
.
R
e
vi
e
w
R
e
g
u
la
to
ry
a
g
e
n
c
y
+
p
h
a
rm
.
in
d
u
st
ry
O
rg
.
+
In
d
.
Q
u
e
st
io
n
n
a
ire
w
ith
4
7
ite
m
s
a
ss
e
ss
in
g
o
rg
a
n
iz
a
tio
n
a
l
d
e
c
is
io
n
m
a
ki
n
g
c
u
ltu
re
a
n
d
a
p
p
ro
a
c
h
,
a
s
w
e
ll
a
s
in
d
iv
id
u
a
lc
o
m
p
e
te
n
c
e
a
n
d
st
yl
e
(N
=
7
6
)
X
X
X
X
X
X
X
X
X
X
3
M
in
d
to
o
ls
,
2
0
1
3
“G
o
o
d
A
re
Y
o
u
r
D
e
c
is
io
n
-M
a
ki
n
g
S
ki
lls
?
”
Q
u
e
st
io
n
n
a
ire
G
e
n
e
ra
l
N
D
In
d
.
Q
u
e
st
io
n
n
a
ire
,
“H
o
w
G
o
o
d
A
re
Y
o
u
r
D
e
c
is
io
n
-M
a
ki
n
g
S
ki
lls
?
”
c
o
n
ta
in
in
g
1
8
ite
m
s
(N
=
N
D
)
X
X
X
X
X
X
X
X
X
4
G
a
rb
u
io
e
t
a
l.,
2
0
1
5
S
u
rv
e
y
o
n
st
ra
te
g
ic
d
e
c
is
io
n
m
a
ki
n
g
C
o
rp
o
ra
te
In
d
u
st
ry
(in
c
lu
d
in
g
p
h
a
rm
.)
O
rg
.
S
u
rv
e
y
(2
8
ite
m
s)
a
ss
e
ss
in
g
re
la
tio
n
sh
ip
b
e
tw
e
e
n
ro
b
u
st
n
e
ss
o
f
a
n
a
ly
si
s,
d
ia
lo
g
u
e
,
a
n
d
d
e
c
is
io
n
-m
a
ki
n
g
e
ff
e
c
tiv
e
n
e
ss
(N
=
6
3
4
)
X
X
X
X
X
X
X
X
5
O
p
e
n
U
n
iv
e
rs
ity
,
2
0
1
3
D
e
c
is
io
n
m
a
ki
n
g
Q
u
e
st
io
n
n
a
ire
G
e
n
e
ra
l
N
D
O
rg
.
+
In
d
.
Q
u
e
st
io
n
n
a
ire
c
o
n
ta
in
in
g
1
2
ite
m
s
in
th
re
e
a
re
a
s:
d
e
c
is
io
n
-m
a
ki
n
g
p
ro
c
e
ss
,
p
sy
c
h
o
lo
g
ic
a
lp
e
rs
p
e
c
tiv
e
a
n
d
th
e
ro
le
o
f
so
c
ia
l
in
flu
e
n
c
e
s
(N
=
N
D
)
X
X
X
X
X
X
X
6
F
is
c
h
e
r
e
t
a
l.,
2
0
1
1
A
st
ru
c
tu
re
d
to
o
lt
o
a
n
a
ly
ze
c
o
ve
ra
g
e
d
e
c
is
io
n
m
a
ki
n
g
H
TA
H
TA
a
g
e
n
c
ie
s
M
e
d
.
Te
n
in
d
ic
a
to
rs
fo
r
a
st
ru
c
tu
re
d
e
m
p
iri
c
a
l
c
o
m
p
a
ris
o
n
o
f
c
o
ve
ra
g
e
d
e
c
is
io
n
s
w
ith
c
o
rr
e
sp
o
n
d
in
g
o
rd
in
a
l
ra
n
ki
n
g
s
(N
=
6
)
X
X
X
X
X
X
7
W
o
o
d
,
2
0
1
2
S
tu
d
y
e
xp
lo
rin
g
in
d
iv
id
u
a
l
d
iff
e
re
n
c
e
s
in
d
e
c
is
io
n
-m
a
ki
n
g
st
yl
e
s
a
s
p
re
d
ic
to
rs
o
f
g
o
o
d
d
e
c
is
io
n
m
a
ki
n
g
G
e
n
e
ra
l
U
n
iv
e
rs
ity
st
u
d
e
n
ts
In
d
.
T
h
re
e
p
a
rt
st
u
d
y:
1
.
G
e
n
e
ra
l
D
e
c
is
io
n
-M
a
ki
n
g
S
ty
le
m
e
a
su
re
(2
5
ite
m
s)
2
.
T
h
e
B
F
Ip
e
rs
o
n
a
lit
y
te
st
(5
0
ite
m
s)
3
.
P
e
e
r
ra
tin
g
s
o
f
d
e
c
is
io
n
-m
a
ki
n
g
q
u
a
lit
y
(2
6
ite
m
s)
.
(N
=
3
1
5
)
X
X
X
X
X
X
(C
o
n
ti
n
u
e
d
)
Frontiers in Pharmacology | www.frontiersin.org 7 April 2017 | Volume 8 | Article 189
Bujar et al. Systematic Review: Medicines’ Decision-Making Processes
T
A
B
L
E
2
|
C
o
n
ti
n
u
e
d
N
o
.
R
e
fe
rn
c
e
s
T
it
le
D
e
c
is
io
n
a
re
a
S
tu
d
y
s
u
b
je
c
t
S
u
b
je
c
t
ty
p
e
M
e
th
o
d
Q
D
M
P
s
e
v
a
lu
a
te
d
1
2
3
4
5
6
7
8
9
1
0
8
B
le
n
ko
e
t
a
l.,
2
0
1
0
D
e
c
is
io
n
a
n
d
o
rg
a
n
iz
a
tio
n
a
l
sc
o
re
c
a
rd
G
e
n
e
ra
l
N
D
O
rg
.
Tw
o
w
e
b
-b
a
se
d
q
u
e
st
io
n
n
a
ire
s,
w
ith
4
a
n
d
1
0
ite
m
s
re
sp
e
c
tiv
e
ly
a
ss
e
ss
in
g
d
e
c
is
io
n
e
ff
e
c
tiv
e
n
e
ss
a
n
d
o
rg
a
n
iz
a
tio
n
a
ld
riv
e
rs
(N
=
1
,0
6
5
)
X
X
X
9
C
o
w
lri
c
k
e
t
a
l.,
2
0
1
1
Q
u
e
st
io
n
n
a
ire
fo
r
a
ss
e
ss
in
g
p
e
rc
e
p
tio
n
o
f
ris
k
th
ro
u
g
h
p
h
a
se
s
o
f
m
e
d
ic
in
e
R
&
D
M
e
d
ic
in
e
s
R
&
D
P
h
a
rm
.
in
d
u
st
ry
In
d
.
Q
u
e
st
io
n
n
a
ire
w
ith
fiv
e
se
ts
o
f
ju
d
g
m
e
n
t
st
a
te
m
e
n
ts
to
a
ss
e
ss
c
a
se
st
u
d
ie
s
fo
r
fo
u
r
m
e
d
ic
in
e
s
(N
=
5
2
)
X
X
X
1
0
M
c
In
ty
re
e
t
a
l.,
2
0
1
2
Q
u
e
st
io
n
n
a
ire
fo
r
a
ss
e
ss
in
g
h
o
w
U
S
F
D
A
A
d
vi
so
ry
C
o
m
m
itt
e
e
M
e
m
b
e
rs
p
re
p
a
re
a
n
d
w
h
a
t
in
flu
e
n
c
e
s
th
e
m
R
e
g
u
la
to
ry
A
d
vi
so
ry
C
o
m
m
itt
e
e
R
e
g
u
la
to
ry
a
g
e
n
c
y
(U
S
F
D
A
)
In
d
.
2
6
-i
te
m
q
u
e
st
io
n
n
a
ire
a
ss
e
ss
in
g
U
S
F
D
A
c
o
m
m
itt
e
e
s’
p
re
p
a
ra
to
ry
p
ra
c
tic
e
s,
in
flu
e
n
c
e
rs
a
n
d
p
re
fe
re
n
c
e
s
(N
=
1
0
1
)
X
X
X
1
1
M
a
ra
n
g
ie
t
a
l.,
2
0
1
4
S
u
rv
e
y
o
f
th
e
It
a
lia
n
M
e
d
ic
in
e
s
A
g
e
n
c
y
(A
IF
A
)
2
0
1
3
R
e
g
u
la
to
ry
A
d
vi
so
ry
C
o
m
m
itt
e
e
R
e
g
u
la
to
ry
a
g
e
n
c
y
(A
IF
A
)
In
d
.
Q
u
e
st
io
n
n
a
ire
,
“S
u
rv
e
y
A
IF
A
2
0
1
3
”
c
o
n
si
st
in
g
o
f
1
7
q
u
e
st
io
n
s,
4
re
g
a
rd
in
g
p
a
rt
ic
ip
a
n
t
in
fo
rm
a
tio
n
a
n
d
1
3
a
ss
e
ss
in
g
in
flu
e
n
c
e
s
o
n
A
IF
A
c
o
m
m
itt
e
e
s
(N
=
7
2
)
X
X
X
1
2
B
e
ye
r
e
t
a
l.,
2
0
1
5
A
fie
ld
st
u
d
y
u
si
n
g
th
e
D
o
m
a
in
S
p
e
c
ifi
c
R
is
k
Ta
ki
n
g
(D
O
S
P
E
R
T
)
sc
a
le
a
n
d
th
e
B
ig
F
iv
e
Ja
c
ks
o
n
In
ve
n
to
ry
(B
F
I)
sc
a
le
R
e
g
.
re
vi
e
w
R
e
g
u
la
to
ry
a
g
e
n
c
y
(E
U
)
In
d
.
T
h
re
e
p
a
rt
q
u
e
st
io
n
n
a
ire
:
1
.
D
e
m
o
g
ra
p
h
ic
d
a
ta
a
n
d
D
O
S
P
E
R
T
sc
a
le
;
2
.
M
e
d
ic
in
e
c
a
se
S
tu
d
y;
3
.
T
h
e
B
F
I
p
e
rs
o
n
a
lit
y
te
st
c
o
n
si
st
in
g
o
f
4
4
ite
m
s
to
a
ss
e
ss
ris
k
p
e
rc
e
p
tio
n
s
o
f
a
ss
e
ss
o
rs
(N
=
7
5
)
X
X
1
3
S
a
le
k
e
t
a
l.,
2
0
1
2
S
c
o
re
c
a
rd
s
to
a
ss
e
ss
th
e
q
u
a
lit
y
o
f
a
re
g
u
la
to
ry
su
b
m
is
si
o
n
a
n
d
its
re
vi
e
w
R
e
g
.
su
b
m
is
si
o
n
a
n
d
re
vi
e
w
R
e
g
.
a
g
e
n
c
ie
s
+
p
h
a
rm
.
in
d
u
st
ry
M
e
d
.
Tw
o
sc
o
re
c
a
rd
s
c
o
n
ta
in
in
g
5
0
ite
m
s
g
ro
u
p
e
d
in
to
se
ve
n
d
o
m
a
in
s:
a
p
p
lic
a
tio
n
fo
rm
a
t,
c
o
n
te
n
t
o
f
th
e
d
o
ss
ie
r,
la
b
e
lin
g
,
sc
ie
n
tifi
c
a
d
vi
c
e
,
c
o
n
d
u
c
t
o
f
th
e
re
vi
e
w
,
c
o
m
m
u
n
ic
a
tio
n
,
a
n
d
o
ve
ra
ll
a
ss
e
ss
m
e
n
t
(N
=
4
)
X
U
S
F
D
A
,
F
o
o
d
a
n
d
D
ru
g
A
d
m
in
is
tr
a
ti
o
n
;
H
T
A
,
h
e
a
lt
h
te
c
h
n
o
lo
g
y
a
s
s
e
s
s
m
e
n
t;
in
d
.,
in
d
iv
id
u
a
l;
m
e
d
.,
m
e
d
ic
in
e
;
N
,
s
a
m
p
le
s
u
b
je
c
t
s
iz
e
u
s
e
d
in
te
s
ti
n
g
;
N
D
,
n
o
t
d
e
fin
e
d
;
o
rg
.,
o
rg
a
n
iz
a
ti
o
n
;
p
h
a
rm
.,
p
h
a
rm
a
c
e
u
ti
c
a
l;
Q
D
M
P,
q
u
a
lit
y
d
e
c
is
io
n
-
m
a
ki
n
g
p
ra
c
ti
c
e
;
re
g
.,
re
g
u
la
to
ry
;
R
&
D
,
re
s
e
a
rc
h
a
n
d
d
e
ve
lo
p
m
e
n
t;
X
,
Q
D
M
P
e
va
lu
a
te
d
b
y
th
e
te
c
h
n
iq
u
e
;
th
e
Q
D
M
P
s
a
re
:
1
,
H
a
ve
a
s
ys
te
m
a
ti
c
,
s
tr
u
c
tu
re
d
a
p
p
ro
a
c
h
to
a
id
d
e
c
is
io
n
m
a
ki
n
g
(c
o
n
s
is
te
n
t,
p
re
d
ic
ta
b
le
a
n
d
ti
m
e
ly
);
2
,
A
s
s
ig
n
c
le
a
r
ro
le
s
a
n
d
re
s
p
o
n
s
ib
ili
ti
e
s
(d
e
c
is
io
n
m
a
ke
rs
,
a
d
vi
s
o
rs
,
c
o
n
tr
ib
u
to
rs
);
3
,
A
s
s
ig
n
va
lu
e
s
a
n
d
re
la
ti
ve
im
p
o
rt
a
n
c
e
to
d
e
c
is
io
n
c
ri
te
ri
a
;
4
,
E
va
lu
a
te
b
o
th
in
te
rn
a
la
n
d
e
xt
e
rn
a
li
n
flu
e
n
c
e
s
/b
ia
s
e
s
;
5
,
E
xa
m
in
e
a
lt
e
rn
a
ti
ve
s
o
lu
ti
o
n
s
;
6
,
C
o
n
s
id
e
r
u
n
c
e
rt
a
in
ty
;
7
,
R
e
-e
va
lu
a
te
a
s
n
e
w
in
fo
rm
a
ti
o
n
b
e
c
o
m
e
s
a
va
ila
b
le
;
8
,
P
e
rf
o
rm
im
p
a
c
t
a
n
a
ly
s
is
o
f
d
e
c
is
io
n
;
9
,
E
n
s
u
re
tr
a
n
s
p
a
re
n
c
y
a
n
d
p
ro
vi
d
e
a
re
c
o
rd
tr
a
il;
1
0
,
E
ff
e
c
ti
ve
ly
c
o
m
m
u
n
ic
a
te
th
e
b
a
s
is
o
f
th
e
d
e
c
is
io
n
.
Frontiers in Pharmacology | www.frontiersin.org 8 April 2017 | Volume 8 | Article 189
Bujar et al. Systematic Review: Medicines’ Decision-Making Processes
did not involve input from regulatory authorities or HTA
agencies, and consequently, it does not assess the issues specific
to those stakeholders.
In summary, the Organizational IQ, which was developed
through studies with a range of R&D organizations, is a 45-
item test that measures corporate decision making across all 10
QDMPs from an organizational point of view only; it has been
assessed in >100 companies, but it has not been developed or
validated within agencies.
Quality of Decision Making Orientation Scheme
(QoDoS; Donelan et al., 2016)
QoDoS is a generic instrument for assessing the quality of
decision making. Its aim is to evaluate the quality of decision
making of individuals and organizations in order to promote
awareness of best practices and biases in decision making. This
should facilitate a clearer understanding of strengths and areas
for improvement, and ultimately encourage a better decision-
making process for both companies and agencies (Donelan et al.,
2016).
The tool was developed and validated using a standardized
approach with both qualitative and quantitative techniques. The
qualitative phase involved semi-structured interviews with 29
key opinion leaders from the pharmaceutical industry (10),
regulatory authorities (9), and contract research organizations
(10) (Donelan et al., 2015). This was followed by content
validity testing, using a panel of experts for language clarity,
completeness, relevance, and scaling, resulting in a favorable
agreement by panel members with an intra-class correlation
coefficient value of 0.89 (95% confidence interval = 0.56,
0.99). The quantitative phase of factor analysis produced a
47-item tool with four domains: Part I = Organizational—
Decision-Making Approach and Decision-Making Culture; Part
II = Individual—Decision-Making Competence and Decision-
Making Style. QoDoS showed high internal consistency (n =
120, Cronbach’s alpha = 0.89), high reproducibility (n = 20,
intra-class correlation = 0.77) and a mean completion time of
10 min (Donelan et al., 2016). Most importantly, QoDoS items
can be mapped to assess the full spectrum of the 10 QDMPs
across different decision points from both the perspective of an
organization and an individual.
The applicability of the tool in a regulatory authority and
pharmaceutical company setting was confirmed through a study
with 76 participants (50% from regulatory authorities and 50%
from pharmaceutical companies). The findings of this pilot
study demonstrate that QoDoS has the practicality to identify
differences in decision making between individuals and their
organization as well as between companies and regulatory
authorities across all 10 QDMPs. Moreover, QoDoS possesses
strong psychometric properties, is easy to understand, and can
be completed in a short time frame. Nevertheless, the tool needs
to be further tested in terms of its sensitivity and reliability,
as well as validated in HTA agencies regarding decision-
making practices during the reimbursement of medicines as
well as evidence submission to support reimbursement of
medicines in pharmaceutical company departments (Bujar et al.,
2016b).
To summarize, the QoDoS is a 47-item test that measures
quality decision making across all 10 QDMPs from an
organizational and individual point of view. It was developed
through studies with the population it was intended for (i.e.,
both the pharmaceutical industry and regulatory authorities); its
applicability has been assessed with 76 participants with more
testing planned in the future.
“How Good Are Your Decision-Making Skills?”
Questionnaire Mindtools, 2013
The aim of this generic web-based questionnaire was to assess
individual decision-making skills and practices. It is composed
of 18 questions that relate to six essential steps in any
decision-making process: establishing a positive decision-making
environment, generating potential solutions, evaluating the
solutions, deciding, checking the decision and communicating
and implementing (Mindtools, 2013).
The method used in the development or validation was not
published, nor any results that were collected from participants.
Overall, this questionnaire assesses nine QDMPs from the point
of view of an individual, but nevertheless does not assess QDMP
10 regarding communication of the decision, and it does not
assess the personal perceptions regarding organizational decision
making. This tool possesses generalizability to other decision
areas and subjects, but it lacks published data on its method used
in development or validity testing to determine its practicality
and robustness.
In summary, this questionnaire is a generic 18-item test
that measures decision making across nine QDMPs from an
individual point of view only; its origin and testing were not
described.
Survey on Strategic Decision Making (Garbuio et al.,
2015)
The aim of this survey was to assess strategic decision making
amongst international companies, including the pharmaceutical
industry. It was used in a study to test three hypotheses
regarding the effect of two dimensions, namely the analysis
performed on the decision and strategic conversations about the
decision (coined “disinterested dialogue”) on decision-making
effectiveness (Garbuio et al., 2015).
The development of the survey was based on a literature
review, previous scholarly works in this area (Dean and
Sharfman, 1996), and interviews with 29 executives from large
corporations. The survey assesses an individual’s perception of
decision making and contains a total of 28 questions focusing
on a key strategic decision made in the past 5 years: eight on
demographic characteristics of the respondents, six variables
measuring robustness of analysis performed, six on disinterested
dialogue, four on strategic decision effectiveness and four control
variables. The Cronbach’s alpha coefficient for strategic decision
effectiveness, robustness of analysis, and disinterested dialogue
were 0.886, 0.793, and 0.716, respectively, which indicates the
survey was appropriately formulated and suitable for the analysis
(Garbuio et al., 2015). These survey items can be mapped
to 8 out of the 10 QDMPs from the point of view of an
individual, mainly regarding “Structure and Approach” (QDMP
Frontiers in Pharmacology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 189
Bujar et al. Systematic Review: Medicines’ Decision-Making Processes
1, 2), “Evaluation” (QDMPs 3, 4, 5, and 6), “Impact” (QDMP
8) as well as communication of the decision (QDMP 10). It
nevertheless does not assess QDMP 7 regarding re-evaluating the
decision with new information, as well as QDMPs 9 regarding
ensuring transparency and providing a record trail.
The survey was sent to 5,210 executives from a global range
of industries, regions, and functional specialties. The response
rate was 45%, which may be due to the lengthy method used
in the study. Exploratory and confirmatory factor analysis was
used to test the hypotheses (Garbuio et al., 2015). Overall, this
survey provided a good overview of some of the perceptions
of organizational-level QDMPs in companies. Nevertheless, the
survey does not evaluate two of the QDMPs, and it does not
assess the individual level decision-making practices, which could
have provided further key insights regarding decision making
in companies. The survey possesses generalizability to be used
in various teams and departments in pharmaceutical companies,
but would need to be validated further in terms of its sensitivity
and reproducibility. Nevertheless it is not appropriate for use
in regulatory authorities and HTA agencies due to the specific
nature of the technique.
To summarize, this technique is a 28-item survey that assesses
corporate strategic decision making from the point of view of
an organization. Consequently it was developed through studies
with just companies (some of which were pharmaceutical) and
subsequently tested with 634 subjects across eight QDMPs; it is
not relevant to agencies.
Open University Decision-Making Questionnaire
(Open University, 2013)
This test was administered as part of a postgraduate course
in Business at the Open University, UK. The aim of the
questionnaire was to help an individual develop greater insight
into their personal decision-making processes (Open University,
2013).
The development or testing of the tool was not published.
The questionnaire is composed of 12 questions assessing decision
making in a recent major decision concentrating on three
areas: formal rational decision-making process; psychological
perspective and focus on the tendency to rely on “heuristics”
(i.e., subjective judgments); and the role of social influences on
decision making. The 12 questions can be mapped to 7 out of
the 10 QDMPs from the point of view of an individual (though
a small number of questions are applicable to organizations
too), excluding QDMP 2 regarding roles and responsibilities and
QDMPs 9 and 10 regarding transparency and communication.
In summary, this technique is a 12-item questionnaire that
assesses decision making from the point of view of an individual
or an organization. Due to its generic nature, it may be applicable
to companies and agencies alike, though this would require
practicality testing and validation. Nevertheless, the development
and testing of the tool were not described and the questionnaire
assessed 7 out of 10 QDMPs.
A Structured Tool to Analyze Coverage Decisions
(Fischer et al., 2011)
This study presents a structured tool that aims to analyze
coverage decision-making processes and drivers. Its purpose was
to compare country-specific reimbursement systems to inform a
number of stakeholder including HTA agencies, manufacturers,
policy-makers, patients, and the public (Fischer et al., 2011).
The tool was developed based on the published conceptual
framework of Rogowski et al. (2008) that identified seven
key components in deciding on the reimbursement of a new
technology. Fifteen semi-structured interviews were conducted
to apply this framework to specific case studies in the
area of cancer prevention with participants from decision-
making institutions from Austria, Sweden, and Lithuania; data
were further validated with publicly available documentation.
From the case studies, the structured scheme describing the
components of reimbursement decision processes and a proposal
of ordinal rankings were deduced and validated through
consultations with experts. The developed scheme contains
eight reimbursement decision-making steps namely: trigger;
participation, publication, assessment, appraisal, reimbursement,
management, and impact (Fischer et al., 2011). Overall, the
tool evaluates six of the QDMPs covering all practices relating
to “Structure and approach,” “Impact,” and “Transparency and
Communication,” but only one QDMP regarding “Evaluation,”
namely QDMP 3 (assign values and relative importance to
decision criteria).
This method was applied to case scenarios with six
medicines and it generated a scheme for structured and
consistent comparison of a large variety of procedural aspects of
reimbursement decision processes. The studymet its purpose and
a robust method was used to develop the scheme. Nevertheless,
the semi-structured phone interviews were considered time
consuming and the scope for interpretation of questions during
interviews was wide. Further validation of the structured scheme
and indicators as well as development of a web-based tool for
more efficient large-scale empirical studies is still needed (Fischer
et al., 2011). Moreover, the scheme does not explicitly assess
QDMPs relating to evaluation, which if incorporated, would
perhaps give more rationale for some of the heterogeneity seen
in the decision outcomes.
In summary, this technique, which was designed based on a
conceptual framework, is a structured tool to analyze coverage
decision making of medicines using 10 indicators across 6
QDMPs. Nevertheless, the tool is specific to evaluating certain
decisions regarding technologies in HTA agencies, and was not
designed to assess general organizational or individual practices
or decision making within companies and regulatory authorities.
Study Exploring Individual Differences in
Decision-Making Styles as Predictors of Good
Decision Making (Wood, 2012)
The aim of this study was to examine the relationship between
decision-making styles and subjective self- and peer-ratings of
decision quality. The second purpose of the study was to evaluate
the incremental validity of decision styles and personality traits
for predicting decision quality (Wood, 2012).
The method involved three phases. Decision style was
measured using Scott and Bruce (1995) General Decision-
Making Style measure; the Big Five Jackson Inventory personality
test (50 items) was conducted using the International Personality
Item Pool short scales (Goldberg, 1999; Goldberg et al., 2006)
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and peer ratings of decision-making quality were collected
using a scale where peers were asked to evaluate their friends’
decision making by rating their habits in four sections. The
first two measures were developed and validated previously;
the third was created for the purpose of this study through
factor analysis and psychometric tests for internal consistency.
Overall, this technique can be used to assess 6 out of 10
QDMPs, including all 5 QDMPs relating to evaluation, as
well as QDMP 1 regarding having a structured approach.
The technique can be used to assess the decision making
of individuals only, but uniquely, the assessment can be
conducted from the point of view of the participants as well as
the perception of peers regarding the ratees’ decision-making
habits.
Three hundred and fifteen target participants from
undergraduate courses at a public university in the Midwestern
United States took part in phases 1 and 2 of the study,
using an online survey administration and data collection
system. In addition, 168 peer raters completed phase 3 of
the study regarding decision-making habits of the target
participants. However, the completion time was not specified,
and there are limitations to the use of the peer rating system,
as indicated by relatively low response rate (53% of phase
1 and 2 participants participated in phase 3). Furthermore,
this technique does not assess organizational-level QDMPs or
individual practices regarding roles and responsibilities, decision
impact, transparency, and communication, as specified by
QDMPs 2, 8, 9, and 10, respectively.
To summarize, this three part study, which aimed to assess
differences in decision-making styles, was designed to be global
in nature, and consequently it may be applicable to any decision
areas as well as be used by any subjects. Nevertheless, it assessed
only 6 QDMPs and the method would require testing and
validation in pharmaceutical companies, regulatory authorities,
and HTA agencies.
Decision Effectiveness and Organizational
Scorecards (Blenko et al., 2010)
The aim of the scorecards was to give a high level assessment
of decision making within organizations, help identify the most
pertinent issues, and guide prioritization of actions on specific
decisions and broader organization enablers. The 2 scorecards
represent step 1, namely “Score your organization,” with a
sequence of five steps to improve decision making (Blenko et al.,
2010).
The method used in the development of the 2 scorecards was
not published. The decision effectiveness scorecard is composed
of four items assessing quality, speed, yield, and effort of the
decision making-process. The organizational scorecard has 10
items and it is used to assess drivers of decision effectiveness
in an organization, namely context, alignment, accountability,
structure, process, information, tools, skills and capabilities,
leadership, and culture. Overall, the 2 scorecards look beyond
decision making as a marker of an effective organization, and
consequently assess 3 out of 10 organizational-level QDMPs,
namely QDMP 1 (structure), 2 (roles and responsibilities), and
10 (communication of the decision).
The scorecards were used to assess 1,065 organizations
including large multinational corporations, entrepreneurial
ventures, research universities, and non-profit institutions,
thereby highlighting the generalizability of this method (Blenko
et al., 2010).
To summarize, this two-part scorecard is generic in nature
and can be used to assess decision making of organizations.
Nevertheless, the approach used in the development and
validation of the scorecards was not described, and none of
the individual-level QDMPs and only three organizational-level
practices can be assessed.
Questionnaire for Assessing Perception of Risk
through Phases of Medicine R&D (Cowlrick et al.,
2011)
This questionnaire was designed to assess risk perceptions in
the pharmaceutical industry and allied healthcare sectors, and is
analogous to the Beyer regulatory authority study (Beyer et al.,
2015) described later in this manuscript. The aim is to investigate
go/no-go judgments in discovery and medicine development in
order to evaluate the influence of personality, experience as well
as demographic traits on decision making (Cowlrick et al., 2011).
The method consists of a web-based questionnaire where
respondents were asked to make five sets of judgment
within case studies regarding four medicines derived from
real scenarios. These five judgments were derived from 18
non-discrete steps relating to the regulatory requirements as
set by the European Medicines Agency (EMA) and the US
Food and Drug Administration (US FDA) and were related
to major key segments in medicines R&D, namely target
selection/ pharmacology; toxicology; biopharmacy and galenics;
and clinical development/market introduction. In addition, the
study assessed to what extent the individual judgments given by
the respondents were influenced by demographics, experience,
or their perceived entrepreneurial character. Paradigms of
entrepreneurial behavior were selected based on previous
research, although the exact process for question design was
not described (Cowlrick et al., 2011). The completion of the
questionnaire takes ∼10 min. Overall, the tool assesses only 3 of
the 10 QDMPs relating to evaluation, namely QDMP 4 (evaluate
internal/external influences/biases), 6 (consider uncertainty), and
7 (re-evaluate as new information becomes available). Due to
the stepwise nature of the cases, this tool offers the potential
to understand whether individuals re-evaluated their decision
making with new information, which was not possible in the
single step decision study by Beyer et al. (2015).
The questionnaire was completed by 52 participants, a
response rate of 62%, which indicated moderate acceptability
(Cowlrick et al., 2011). The authors did not describe how the
method used was developed, compared with the Beyer et al.
(2015) study in which validated tools were used, but nevertheless,
this technique was less time intensive.
In summary, this questionnaire was used to assess decision
making during the medicines R&D across three QDMPs from
the point of view of an individual only. The design of the
questionnaire is unknown. Furthermore, the questions are
generalizable to other stakeholders, whereas the case studies are
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specific to the pharmaceutical industry and would require major
modifications and further validation if to be used in regulatory
authorities and HTA agencies.
Questionnaire for Assessing How US FDA Advisory
Committee Members Prepare and What Influences
Them (McIntyre et al., 2012)
This qualitative study was carried out to understand preparatory
practices, influencers, and preferences of US FDA advisory
committees regarding materials provided by the sponsor and
the FDA, advisory committee presentations and Q&A sessions.
The goal was to understand what advisory committee members
want from sponsors to enable their informed participation in the
meetings (McIntyre et al., 2012).
It consisted of a web-based survey composed of 26 questions,
with a target completion time of 10 min. The method
used in the design and validation of the questions was not
described. This survey assesses a limited set of decision-making
practices, namely QDMP 4, 5, and 7 regarding evaluation of
influences/biases, examination of alternatives and re-evaluation
with new information respectively from the point of view of an
individual only.
The qualitative questionnaire was administered to 101 current
or former members of one of the US FDA public biomedical
advisory committees. The advantages are a short completion
time and that the questionnaire captured the relevant individual
practices and influences regarding evaluation of material for
committee meetings (McIntyre et al., 2012). Moreover, the survey
does not evaluate 7 out of the 10 individual practices, or what the
individuals think about the practices of the organization (in this
case, the committee). This is likely due to the fact that this was
outside the scope of this study.
In summary, this 26-item questionnaire was used to assess
decision making of the US FDA Advisory Committee across
three QDMPs from the point of view of an individual only.
Nevertheless, the development and validation of the questions
were not published. Although this questionnaire could be
adopted for other regulatory bodies, the questions are specific
to committee decision making and have limited transferability to
other regulatory areas as well-stakeholders such as industry and
HTA agencies.
Survey of the Italian Medicines Agency (AIFA) 2013
(Marangi et al., 2014)
A questionnaire that was analogous to US FDA’s was undertaken
by AIFA in 2013 to assess the influences on agency committees
and secretariats’ opinions and decisions. This study was part
of an initiative to enhance a transparency-oriented policy and
improve information exchange as well as decision making with
stakeholders (Marangi et al., 2014).
The study was a web-based questionnaire with a completion
time of 7 min and a total of 17 questions assessing the
demographics, professional qualifications, and committee
experiences, followed by questions regarding internal and
external influences on committees and secretariat member
opinions. The method used in the design of the questions was
not described. Similar to the US FDA study, the questions
are specific to AIFA advisory committee meetings and the
survey assesses a narrow set of individual QDMPs relating to
decision-making evaluation practices only (QDMP 4, 5, and 7).
A total of 72 participants from AIFA committees, secretariats,
and subcommission members took part in the study (Marangi
et al., 2014). This qualitative survey can be completed in a
short timeframe, but the development of the questions was not
described.
To summarize, this 17-item questionnaire was used to assess
decision making of the AIFA Advisory Committee across three
QDMPs from the point of view of an individual only. Moreover,
the origin of the questionnaire has not been published. Although
the questionnaire meets its objectives, it is not transferable
outside the regulatory advisory committee setting to industry and
HTA agencies.
A Field Study Using the Domain-Specific Risk Taking
(DOSPERT) Scale and the Big Five Jackson Inventory
(BFI) Scale (Beyer et al., 2015)
This set of tests aimed to assess the influence of risk attitudes
and personality traits on clinical decision making of expert
regulators. The two main objectives of the study were to describe
the distribution of risk attitudes among medical assessors within
EMA and to measure their personality traits and cross-domain
risk attitudes (Beyer et al., 2015).
This study was implemented as a web-based questionnaire
and was composed of three well-defined phases using validated
tests; phase 1: demographic data and 30-item DOSPERT scale
to measure risk appetite; phase 2: medicine case study using
mock “clinical dossiers” for three medicines and eight rating
scales on benefit-risk dimensions; and phase 3: The BFI 44-
item personality test. Ordinal regression models were used to
evaluate the relationships between the variables regarding risk
taking, personality as well as the assessment of benefit and
risk of a medicine (Beyer et al., 2015). Although the study
evaluates the relationship between perception of uncertainty
and personal influences as defined by QDMP 4 and 6, it
does not evaluate any of the practices relating to decision
making “structure and approach,” “impact,” or “transparency and
communication” of decision making. Indeed other individual
as well as organizational decision-making practices should be
explored in order to understand the broader context of these
findings.
This technique was used to assess 75 assessors from European
regulatory authorities. It utilizes validated methods and it meets
its purpose of assessing risk attitudes in medical assessors (Beyer
et al., 2015). It also possesses generalizability to be tested in
other agencies, but would need to be adapted for companies and
HTA agencies with some modifications to phase 2 (medicine case
study). A major drawback of this technique is that it is resource
and time intensive for both the assessors and researchers.
To summarize, this three part questionnaire was used to assess
decision making of regulatory assessors. The development of the
study was well-described, but it can only be used to assess 2 out
of 10 QDMPs and it does not evaluate the perceptions of the
individuals regarding their organization.
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Scorecards to Assess the Quality of a Regulatory
Submission and Its Review (Salek et al., 2012)
Two scorecards were developed to enable companies to assess the
quality of the regulatory review and for regulatory authorities
to assess the quality of submission relating to a specific
product. This allows for a unique comparison of the quality
of the submission compared to review, as well as inter-
product, company, or agency cross-evaluations (Salek et al.,
2012).
The scorecards were developed through a structured and
well-described process of conceptualization (expert discussions;
bibliography review), item generation (literature review; expert
input), and reduction (qualitative reduction; content validation).
Each scorecard includes more than 50 items that are grouped
into seven domains (application format, content, labeling,
scientific advice, conduct of the review, communication, and
overall assessment). The 2 scorecards enable a quantitative
assessment of the quality of the information and communication
specific to dossiers and go beyond just decision making as
a marker of quality (Salek et al., 2012). As a consequence
they evaluate whether a structured approach was taken
(QDMP 1), but do not evaluate the roles and responsibilities
of an individual/organization (QDMP 2) or the quality of
individual and organizational decision making as outlined
in QDMP 3, 4, 5, 6, and 7, which are related to the
evaluation practices as well as preferences, or QDMP 8, 9,
and 10 which assess decision-making transparency and decision
communication.
The scorecards were tested by three major regulatory
authorities and four international pharmaceutical companies
based on the same four products. The majority of respondents
agreed that the scorecards covered all critical factors that
affect the quality of the dossier and the review. A number of
modifications were made following a pilot study, particularly the
inclusion of definitions for each rating response option, which
further added to the robustness of the scorecards (Salek et al.,
2012).
The high response rate as well as positive feedback indicated
their practicality, clarity, and applicability, whilst the method
used was well-described. The scorecards can be used for
different regulatory procedures and across different teams, and
can be therefore applied to optimize the regulatory authority
and company processes. Importantly, this technique encourages
open internal and external dialogue. Although the scorecards
meet their purpose of assessing the quality of review and
submission, it can be argued that aspects specific to decision
making, other than having a structured approach (QDMP
1), need to also be addressed to ensure that companies and
agencies are not only embedding good review and submission
practices, but are also making quality decisions (Liberti et al.,
2013).
In summary, the scorecards can be used to assess the quality
of regulatory submission and review, and were developed using a
well-defined framework using input from regulatory authorities
and companies. Nevertheless, they only assess one QDMP and
are outside the scope of HTA agencies; a separate set of scorecards
would need to be developed and validated for this purpose.
Part 3: Measurement Properties of the
Techniques for Evaluating Quality of
Decision Making
The 13 techniques were evaluated in terms of their measurement
properties, according to six key criteria (McDowell, 2006; Streiner
et al., 2015), namely theoretical underpinning (development
technique was based on a well-described methodological
framework); psychometric properties (development of technique
involved psychometric tests, content validity, and internal
consistency); psychometric evaluations (the validity, reliability,
and sensitivity of the tool was demonstrated); demonstrated
practicality (the technique was applied to target population
through pilot studies); generalizability (the technique can be
used across industry, regulatory, and HTA); and applicability
(the technique is applicable to evaluating individuals and
organizations). The techniques were listed in a descending order
by total number of criteria met, followed by year of publication
(Table 3). Only five properties are shown in Table 3, as none of
the techniques underwent psychometric evaluations.
Out of the 13 articles, only one met all criteria described in
Table 3. Eleven (85%) of the techniques met at least two criteria,
namely demonstrated practicality, followed by theoretical
underpinning (8, 62%). On the other hand, the criteria that
were met by the minority of the techniques were generalizability
of study subjects (5, 38%); psychometric properties (3, 23%);
and applicability to both assessing individuals and organizations
(2, 15%). None of the 13 techniques met the criteria
of psychometric evaluations regarding the demonstration
of sensitivity/responsiveness (detecting change over time),
construct validity (demonstrating strong correlation with closely
related measures—i.e., convergent validity; and poor correlation
with distantly related measures—i.e., divergent validity); and
reliability (producing similar results under consistent conditions)
and were consequently not illustrated in Table 3.
DISCUSSION
This is the first literature review that has identified techniques
for evaluating the quality of the decision-making process in
medicines’ development, regulatory review, and HTA. The
objectives were to compare the existing techniques, assess their
properties, identify research gaps, and recommend the next steps.
This literature review has demonstrated that the area of quality
decision making has been explored to a certain extent, but in
a fragmented way, where studies have been independent, few
have been replicated, and there is no overarchingmutually agreed
conceptual framework.
This is consistent with previous research which has identified
that the majority of pharmaceutical companies and regulatory
authorities do not have formal assessments in place to
periodically measure the quality of their decision making (Bujar
et al., 2016a) and this could be partially explained by the fact
that very few appropriate techniques exist to enable this to be
done. Nevertheless, both of these stakeholders believe that such
measurements of quality decision making would be possible
and would improve practices for individuals and organizations,
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which could be achieved by utilizing the best techniques currently
available (Bujar et al., 2016a). Consequently, there is a need to
identify a technique that is relevant, robust and can be applied
to pharmaceutical companies, regulatory authorities and HTA
agencies.
It should be noted that most of the techniques are suitably
robust to be used in the area they were created for, and therefore
should be utilized for their specific purposes despite not having
the applicability across all three stakeholders. Nevertheless, an
advantage of having a tool valid across all three stakeholders
would be the ability to discuss, share and compare challenges
in decision making using a common terminology. Already
companies, regulatory and HTA agencies have been collaborating
regarding topics such as parallel scientific advice (EMA, 2016),
real world evidence generation (McAuslane et al., 2016a) as well
as parallel regulatory and HTA reviews (McAuslane et al., 2016b),
and it would be of interest to align best practices in decision
making across the three groups.
Key Trends and Features of Existing
Techniques
This review identified 13 techniques for evaluating the quality of
decision-making process in medicines’ development, regulatory
review, and HTA. This is a relatively low number, considering
the increasing pressure on pharmaceutical companies, regulatory
authorities, and HTA agencies to make the best-quality decisions
(Liberti et al., 2013). Moreover, routine assessment of the
quality of the decision-making process (as opposed to just
measuring outcomes) has been recognized as key for improving
the productivity of any organization (Kahneman, 2011).
Out of the 13 techniques, 1, the Organizational IQ, was
developed in 1998, and 12 were published from 2010 onward.
This indicates that although some initial work was done early on
and stands ahead of its time, it is only in more recent years that
measuring decision making or understanding decision making
styles and approaches has become of interest in this arena.
The 13 techniques have unique aims as well as strengths and
weaknesses based on their origin and the methods that were
used in their development and testing. Furthermore, they can be
classified into three groups described below.
Group 1: Seven Specific Research Techniques for
Assessing the Quality of the Decision
Making-Process in Medicines’ Development,
Regulatory Review, or HTA
An examination of the seven techniques developed specifically
to assess decision making in the area of medicines’ development,
regulatory review, or HTA demonstrated that a number of
were developed to meet the needs of a particular organization,
for example to increase transparency of regulatory advisory
committee meetings within AIFA and US FDA (McIntyre et al.,
2012; Marangi et al., 2014). Nevertheless, although these two
surveys are practical for their purpose and are characterized by
low resource intensity, their design was not described and their
latitude for generalizability andmeasurement against the QDMPs
is limited due to their specific scope.
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Other techniques, as exemplified by the work of Beyer et al.
(2015) and Cowlrick et al. (2011) were developed as research tools
to measure the effect of risk attitudes and personality traits on
decision making regarding medicines’ development and review.
These studies developed and tested a number of interesting
hypotheses, but are resource intensive, and are limited to the
specific decision area as well as to the subjects they were designed
to assess. Finally, a number of techniques evaluate more than just
decisionmaking as a marker of quality, such as the “Scorecards to
Assess the Quality of Regulatory Submission and Review” (Salek
et al., 2012) and the “Structural tool to analyze coverage decision
making” (Fischer et al., 2011) and may represent promising
techniques to study the general area of quality to assess the
effectiveness of an organization or an outcome (Fischer et al.,
2011; Salek et al., 2012).
The last technique in this group “Survey on strategic
decision making” (Garbuio et al., 2015) looked specifically
at corporate decision making, which is applicable to
pharmaceutical companies (i.e., medicines’ development).
Although the tool was developed based on a well-designed
methodological framework and demonstrated practicality in
companies, it is resource intensive and does not possess the
generalizability to allow its application to other subjects such
as regulatory authorities or HTA agencies or to individuals (as
opposed to just organizations) due to the specific nature
of the questions. It is important to note that, all seven
of these techniques were used primarily for research or
as one-off studies, but they have not been systematically
adopted for use by companies, regulatory authorities or
HTA agencies. Overall, none of these seven techniques are
appropriate to measure decision making quality due to low
generalizability as well as an inability to measure all 10
QDMPs.
Group 2: Four Educational or Consulting Techniques
for Assessing the Quality of the Decision-Making
Process
Four of the techniques were either developed for educational
purposes or by consulting groups to assess decision making
in general (Blenko et al., 2010; Wood, 2012; Mindtools, 2013;
Open University, 2013). Consequently, although all four possess
good generalizability to be applied to industry, regulatory
authorities, and HTA agencies, only one of the techniques has
published information regarding its design and psychometric
properties (Wood, 2012), while only two have demonstrated
practicality through pilot studies (Blenko et al., 2010; Wood,
2012). As well as that, only one of the techniques has the
applicability to measure decision making in both individuals
and organizations (Open University, 2013). Consequently, these
may be useful generic tools for informal assessments of decision
making, but due to lack of published data regarding their
design and measurement properties, as well as a lack of
applicability to individuals and organizations across the 10
QDMPS, these techniques lack robustness to formally evaluate
quality decisionmaking in companies, regulatory authorities, and
HTA agencies.
Group 3: The Two Most Promising Techniques for
Assessing the Quality of the Decision-Making
Process
Only 2 of the 13 techniques evaluated the full spectrum of
the 10 QDMPs, namely the Organizational IQ (Matheson and
Matheson, 1998) and QoDoS (please see the Appendix in
Supplementary Material; Donelan et al., 2016). Incidentally, the
two instruments possess a similar number of items (45 for
Organizational IQ and 47 for QoDoS) and can therefore be
completed in a short timeframe. Both techniques were designed
based on a well-hypothesized conceptual and well-described
methodological framework and demonstrated practicality in the
target populations, but only QoDoS underwent psychometric
testing during its design, namely content validity and internal
consistency. It is nevertheless interesting and significant that
these twomost promising techniques for quality decision making
were developed independently, with a 20-year time gap between
them and both resulted in similar key features.
The second area of disparity is that the Organizational
IQ test, unlike QoDoS, does not assess the practices of both
individuals and organizations, but just the latter. Although it
could be argued that this is sufficient as individuals make up
an organization, assessing individuals is also key as people
tend to score themselves more favorably but be more critical
of an organization (Bujar et al., 2016b). While this could
be a potential sign of bias, areas of disparity between the
individuals and organizations could also indicate deficiencies
in practices within companies, agencies and committees, as
changes in individuals could translate into better organizational
practices. Consequently, assessment with QoDoS gives a unique
perspective of both groups which helps to identify areas for
improvement.
In the third area of divergence between the two techniques,
the development of the Organizational IQ test was based
on research among R&D organizations, and consequently the
factors in decision making specific to regulatory authorities
and HTA agencies were not incorporated into the instrument.
Nevertheless the Organizational IQ test represents a practical
approach and possibly a gold standard for measuring decision
making of pharmaceutical and other companies. In contrast,
QoDoS was developed specifically to look at decision making
in the area of medicines’ development and regulatory review,
based on interviews with key opinion leaders from agencies and
companies. It is therefore a more appropriate tool compared
with the Organizational IQ test to measure quality decision
making in pharmaceutical companies, regulatory authorities,
and HTA agencies and moreover it can be applied to identify
commonalities and differences between the various stakeholders
as well as strengths and areas for improvement (Bujar et al.,
2016b). Most importantly, it can increase an awareness of
the biases and influences that need to be considered when
making decisions, as well as the best practices that should be
incorporated into a decision-making framework. Although the
psychometric evaluation of QoDoS has been partially established,
further testing is still required to demonstrate practicality in
HTA agencies, as well as its construct validity, sensitivity and
reliability.
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Emerging Research Themes
A secondary outcome of this review has been the identification
of research themes and hypotheses regarding decision making
preferences and influences. These have been derived from the
pilot studies conducted using the identified techniques and
instruments. A selection of the key findings is described below.
The research themes identified through the work of Beyer
et al. (2015) as well as Cowlrick et al. (2011) relate to the impact
of personality traits, functional role, education, and gender on
decisionmaking of individuals within pharmaceutical companies
and regulatory authorities. Both studies demonstrate that these
factors can explain the variability in judgments and decision
making techniques within organizations. Moreover, the study by
Beyer et al. (2015) demonstrated that “conscientiousness” (being
thorough and careful) predicted an increase in the perception
of a medicine’s benefits, whereas extraverted disposition was
predictive of seeing fewer risks, and interestingly, male assessors
gave higher scores for a medicine’s benefit ratings than did female
assessors. Importantly, these research findings are in line with
general research on decision making and risk taking (Thaler and
Sustein, 2009; Lovallo and Sibony, 2010; Kahneman, 2011; SDG,
2011) and emphasize that despite sound scientific knowledge
and experience, individuals within agencies and companies are
equally prone to biases and reliance on emotional judgments
when compared with lay people. Moreover, individuals are likely
to rate their performance as superior to their organization
(Bujar et al., 2016b). This has already been emphasized in
a number of recent studies, which have discussed the role
of informal factors in decision making, relating to biases
and behaviors, which influence the decision-making processes
during the delivery of dossiers for regulatory submissions as
well as during the medicine evaluation process (Tafuri, 2013;
Cook et al., 2014; Donelan et al., 2015). Furthermore, the
occurrence of biases within organizations or their influence
on decision making was perceived by regulatory authorities
and pharmaceutical companies as one of the major barriers
to ensuring quality decision making. This emphasizes the
importance of implementing a decision-making framework and
incorporating the 10 QDMPs, particularly making decision
values, preferences and uncertainty more explicit, as suggested
by pharmaceutical companies and regulatory agencies in order to
ensure that quality decisions are made throughout the life cycle
of medicines (Bujar et al., 2016a).
The two surveys described by McIntyre et al. (2012) and
Marangi et al. (2014), which studied the decision making
of the US FDA and the Italian AIFA Advisory Committees
regarding how the members prepare for meetings and what
influences their decision-making, interestingly both concluded
a number of similar findings. Those included a diverse range
of practices utilized by the members as well as potential biases
that influence the decision making that may subsequently need
closer monitoring. Both studies identified that a large proportion
of individuals attend committee meetings having already decided
how to vote. As well as that, the members are seldom influenced
by external stakeholders such as healthcare professionals,
patients, and sponsors, despite finding their input important.
On the other hand, the members are frequently influenced
by internal committee members, particularly colleagues or the
committee chair. Both studies suggest that in addition to already
minimizing biases due to conflicts of interest, the agencies
should considermeasuring the impact of the so-called intellectual
bias on decision making during meetings, which may lead
the committee members believing information which appears
more favorable or familiar. Moreover, better practices could be
achieved by implementing the 10 QDMPs into agency processes
that promote having a structured approach to decision making
(QDMP 1), assigning values to decision criteria (QDMP 3),
evaluating different alternatives (QDMP 5), and new information
(QDMP 7), andmore importantly, evaluating different influences
and biases (QDMP 4) to ensure that structured decisions are
made during the review of medicines. It would be of interest
to widen the scope of such studies to other regulatory agencies,
as well as HTA committees in order to address the uncertainty
surrounding the process for appraising whether or not medicines
should be recommended for reimbursement (Calnan et al.,
2017).
Finally, the research by Garbuio et al. (2015) assessed decision
making amongst international companies through a study of
634 outcomes made by executives across multiple industries,
including the pharmaceutical industry. This study demonstrated
first of all that strategic decision making is important for decision
effectiveness. Secondly, the study found that robust analysis
of data and strategic conversations and communication during
decision making around the data (“disinterested dialogue”)
have a significant positive relationship with decision-making
effectiveness. Moreover, the findings demonstrated that the
strategic conversations have in fact more impact on decision
effectiveness than analysis of data. This is consistent with
previous research in this area, such as that by Westley (1990)
where managers were interviewed regarding challenges on
strategic making; for example the difficulties in not being
included in strategic meetings but being given lengthy reports
instead, as expressed by one of the interviewees: “just looking at
the numbers doesn’t give me the insights. It does not give me to
total picture. I don’t know how they (executives) are interpreting
those numbers.”
This emphasizes the importance of QDMP 10 regarding
communication during decision making, as well as QDMP 9 to
ensure transparency and provide a record trail of the process
through which the decision was made. Despite its apparent
importance, QDMPs 9 and 10 were the least assessed practices
by the 13 decision-making techniques identified in this review.
Consequently these practices may require closer evaluation
and better incorporation into the decision-making practices of
individuals and organizations to ensure decision effectiveness.
Research Limitations
The present study was limited to existing, published techniques
for assessing the quality of decision making using a web-based
literature review of peer-reviewed journal articles found through
sources described earlier. There may be other techniques or
instruments that have not been formalized or published in the
English language and were therefore not included. In addition,
there may be data regarding the development and testing of the
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included techniques that have not been published, and which
could have subsequently influenced the assessment of the tools.
CONCLUSIONS
This review identified a general paucity of research in the area
of decision making in medicines’ development and review, but
particularly in the area of HTA. This applies to the development
as well as the systematic application of techniques for evaluating
quality decision making and lack of consensus around a gold
standard. This review found 13 techniques that can be used
to assess the quality of decision making by pharmaceutical
companies, regulatory authorities, and HTA agencies in order
to ultimately enable a more consistent and transparent process.
Although some of these techniques are scientifically sound and
have been developed and tested using robust methodologies,
the majority do not possess generalizability to be applied across
companies, regulatory authorities, and HTA agencies, and only
a proportion have demonstrated practicality and applicability
to measure decision making in individuals and organizations
against all 10 QDMPs. Indeed, assessing the quality of decision
making using a common technique can provide a basis for
clear dialogue of issues in decision making within the three
stakeholders and ultimately build trust and understanding
of what issues are common and which are specific to the
three stakeholders. There is also a need to develop for more
transparency around how some of the existing techniques and
instruments were developed, as well as more testing and routine
application for the most promising techniques.
Out of the 13 techniques reviewed, 2, Organizational IQ and
QoDoS, have been identified as the most promising, as they
conform to all 10 QDMPs. Nevertheless, the Organizational IQ
can only be applied to the pharmaceutical industry from an
organizational point of view, whereas QoDoS has the potential
to capture the issues of companies and agencies alike, as well
as evaluating both individuals and their perception of their
organizations. This could render QoDoS as the most appropriate
measure relative to the other techniques identified. The next steps
would be to further test the validity, sensitivity, and reliability
of QoDoS across the relevant stakeholders. The overall benefit
of systematically assessing the quality of decision making with
QoDoS is to enable an increased awareness of biases and best
practices but also provide the ability to measure change over
time in order to determine the impact of improvement initiatives.
Furthermore, such measurements of quality will enable trust,
consistency, transparency and timeliness to be built into critical
decisions in medicines’ development, regulatory review, and
HTA.
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